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Inﬂuenza infection after allogeneic hematopoietic cell transplantation (allo-HCT) can result in severe
complications. The effectiveness of the annual vaccine depends on age, immune competence, and the anti-
genic potential of the 3 strains included. We hypothesized that a second vaccine dose, the standard of care for
vaccine-naïve children, might improve post hematopoietic cell transplantation (HCT) immune responses.
Patients >60 days post-HCT were randomized to receive either 1 (n ¼ 33) or 2 (n ¼ 32) inﬂuenza vaccine
doses separated by 1 month. The primary endpoint was whether 2 vaccinations induced superior immunity;
however, we found no difference. Secondary endpoints were to identify variables associated with responses.
Both hemagglutination inhibition (HI; P < .005) and ELISpot responses (P ¼ .03) were greater for patients
vaccinated 1 year posttransplantation. Umbilical cord blood (UCB) recipients showed less IFN-g responses
(P < .001). Interestingly, there was a positive correlation between the total number of CD19þ cells before
vaccination and seroconversion (P ¼ .01) and an inverse correlation for IFN-g responses (P ¼ .05). Variables
not associated with vaccine responses included prevaccine CD4þ cell counts (total, naïve, or memory), steroid
usage at vaccination, age, or conditioning intensity. Time from transplantation to vaccination and absolute
CD19þ cell counts were the strongest predictors of vaccine responses. Methods to improve inﬂuenza vaccine
responses after allo-HCT are needed.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Early after allogeneic hematopoietic cell transplantation
(allo-HCT), inﬂuenza infection causes an illness that ranges
from a mild viral syndrome to a severe life-threatening
illness [1,2]. The incidence of inﬂuenza infection in the
early transplantation period ranges from 14% to 20% in adult
patients who underwent allo-HCT with a respiratory illness
[3,4]. Mortality rates after inﬂuenza infection in trans-
plantation recipients in the 1980s to 1990s have been re-
ported to be as high as 50% to 85% [5-7]. However, recent
data suggest an overall decrease in mortality. For instance,
Nichols et al. [8] noted 10% mortality within 30 days of
inﬂuenza infection after hematopoietic stem cell trans-
plantation (HSCT), likely related to improved supportive care
measures [9]. Although encouraging, the recent develop-
ment of antiviral-resistant strains of inﬂuenza that have been
reported in patients who undergo HSCT, clearly have the
potential to increase overall mortality [10].
Severe, life-threatening infections, including inﬂuenza,
are more common in the immediate posttransplantation
period when lymphopenia is prevalent and marked [4,8,11].dgments on page 115.
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12.08.015Vaccination against inﬂuenza has the potential to provide
life-saving immunity to the virus [12]. However, inﬂuenza
vaccination early after transplantation results in suboptimal
responses [8,13,14], and the ideal posttransplantation
vaccine schedule has yet to be established. Newer ways to
improve immune responses to vaccinations after HSCT are
being explored and include vaccinating the donor before
harvest. However, this is not always possible, especially with
umbilical cord blood (UCB) graft sources. Previous American
Society for Blood and Marrow Transplantation and European
Group for Blood and Marrow Transplantation guidelines
have been consolidated into Center for International Blood
andMarrow Transplant Research guidelines and recommend
yearly inﬂuenza vaccinations starting between 4 and 6
months after HSCT, as well as providing a yearly vaccination
for household contacts [15]. Vaccination guidelines for
healthy children, recommended by the Centers for Disease
Control, state that those <9 years of age who have never
been immunized against inﬂuenza should receive 2 doses
separated by 4 weeks [16]. This is supported, in part, by an
efﬁcacy study in healthy vaccine-naïve children [17].
The current practice is to vaccinate patients against
inﬂuenza early after allo-HCT with a single vaccination.
However, in previously unvaccinated children, 2 vaccinations
invoke better immune responses [17,18]. In 1993, the
approach of using 2 vaccine doses was tested in a small
cohort of patients after allo-HCT. Although T cell responses
were not tested, the investigators were unable to show anyTransplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Patient Characteristics between One- and Two-Vaccine Dose Groups
Factors Randomization Group Total P Value
Single Shot Double Shot
Total 33 32 65
Patient/donor CMV serostatus .53
Negative/negative 12 (40%) 11 (34%) 23
Negative/positive 1 (3%) 0 1
Positive/positive 17 (57%) 21 (66%) 38
Conditioning .77
Cy/TBI 14 (42%) 12 (38%) 26
Cy/Flu/TBI 12 (36%) 15 (47%) 27
Bu/Cy containing 4 (12%) 2 (6%) 6
Other 23 (9%) 3 (9%) 6
Non-MA conditioning 12 (36%) 14 (44%) 26 .54
GVHD prophylaxis .68
T cell deplete 0 1 (3%) 1
CSA/MMF 16 (48%) 17 (53%) 33
CSA containing 11 (33%) 8 (25%) 19
Other 6 (18%) 6 (19%) 12
Age
18 25 (76%) 23 (72%) 48 .72
<9 3 (4%) 5 (7%) 8 .26
Median (range), (interquartile range) 39 (8-62), (32-50) 42 (4-68), (15-52) 40 (4-68), (16-51) .62
Donor type .77
MRD 16 (48%) 19 (59%) 35
Mismatched URD 4 (12%) 3 (9%) 7
UCB 13 (39%) 10 (31%) 23
Gender: male 20 (61%) 19 (59%) 39 .92
Race: white 26 (79%) 27 (84%) 53 .75
Years from transplantation to vaccination
Median (range), (interquartile range) 0.7 (0.2-19.7), (0.2-2.0) 1.0 (0.2-7.0), (0.3-2.0) 0.9 (0.2-19.7), (0.2-2.0) .40
CMV indicates cytomegalovirus; Cy, cyclophosphamide; TBI, total body irradiation; Flu, ﬂudarabine; Bu, busulfan; MA, myeloablative; GVHD, graft-versus-host
disease; CSA, cyclosporine A; MMF, mycophenolate mofetil; MRD, matched related donor; URD, unrelated donor; UCB, umbilical cord blood; Tx, transplantation.
Patients were randomized to receive 1 or 2 vaccine doses.
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tantly, this study was performed after severe immuno-
depletion (by adding alemtuzumab in the preparative
regimen), thus, the issue of whether 2 vaccine doses enhance
inﬂuenza-speciﬁc immunity after allo-HCT is unresolved.
Here, in a randomized study, we tested the hypothesis that
allo-HCT recipients who receive a second inﬂuenza vaccine
will have stronger vaccine-speciﬁc immune responses.
Secondary goals of this study were to identify other variables
associated with the likelihood of inﬂuenza vaccination
responses.
METHODS
Study Design and Procedures
Patients were screened from September 2010 to February 2011 for study
eligibility during routine posttransplantation clinic appointments. To be
eligible, patients had to be>60 days after allo-HCT, have neutrophil recovery,
be in remission, and assessed to be well enough to receive the vaccine.
Patients were ineligible if they had received any of the following: i.v.
immunoglobulin within the previous 3 months, alemtuzumab within
6 months, or the inﬂuenza vaccine within 4 months of study entry. Written
informed consentwas obtained frompatients (or parents if<18 years old) for
this institutional review board-approved study (study #NCT01215981).
Blood was collected at the time of enrollment before the ﬁrst vaccination
(Fluzone, Sanoﬁ-Pasteur, PA) according to the manufacturer’s recommen-
dations. Four weeks after vaccination, patients were randomized to receive
a second vaccine dose and blood was again collected. If applicable, a second
vaccine dose was then administered. Finally, patients returned at 8 weeks
after enrollment for blood collection. From the blood samples, sera and
peripheral blood mononuclear cells (PBMCs) were isolated and stored
at 20C or liquid nitrogen, respectively. The randomization between 1 or 2
vaccine doses was stratiﬁed by age (18 and <18 years) and steroid use
(present or absent). As the primary endpoint of this study was to determine
whether 2 vaccinedoses resulted in superior immune responses compared to
a single vaccine, we used immune response to power enrollment. Because
viral strains in thevaccinepotentiallyvary fromyear toyear, andAb titersmay
differ, we focused on increases in T cell-based (ELISpot) responses. Assuminga baseline proportion of patients responding to a single vaccine dose of 40%,
our sample was sufﬁcient to detect a 30% increase in response rate.
Transplantation Procedures
Patients enrolled in this trial received either MA preparative regimens
(n ¼ 39) or reduced-intensity conditioning (RIC; n ¼ 26). Total body irra-
diation (TBI) was used in 86% of the conditioning regimens. Graft-versus-
host disease (GVHD) prophylaxis consisted of cyclosporine A (CSA) and
mycophenolate mofetil (n ¼ 33), another CSA-containing regimen (n ¼ 19)
or other combinations (n ¼ 10) (Table 1). The presence or history of GVHD,
whether acute GVHD or chronic GVHD, was not an exclusion criteria, and
patients on steroids at the time of enrollment (n ¼ 22) were stratiﬁed to be
evenly distributed between the 2 randomization groups. Detailed infor-
mation about steroid dosing is listed in Supplemental Table S1.
Determination of Lymphocyte Subsets before Vaccination
Before vaccination, PBMCs were obtained and cryopreserved. T and
B cell immunophenotyping was performed in bulk. For T cells, Abs against
CD3, CD4, and CD8 were used to identify the percentages of total T cells
(CD3þ) and CD4þ and CD8þ T cell fractions (CD3þCD4þ and CD3þCD8þ,
respectively). CD4 and CD8 T cell subsets were distinguished using
CD45RA and CD27 to identify naïve (CD45RAþCD27þ), central memory
(CD45RACD27þ), effector memory (CD45RACD27), and effector memory
RAþ cells (CD45RAþCD27). For B cells, CD19, IgD, and CD27 were used to
identify naïve (CD19þIgDþCD27), unswitchedmemory (CD19þIgDþCD27þ),
switched memory (CD19þIgDCD27þ), and double-negative cells
(CD19þIgDCD27). Natural killer (NK) cells were identiﬁed by gating on the
CD3 fraction and thenbyusing aCD56þCD16 andCD56þCD16þphenotype.
The total number of each cell populationwas determined using the following
formula: absolute lymphocyte count at the time of blood sampling 
percentage of the population of interest as determined by ﬂuorescent acti-
vated cell sorter.
Antibody Responses
The hemagglutinin inhibition (HI) assay was conducted as described
previously [20]. Brieﬂy, human sera samples were treated with receptor-
destroying enzyme (Denka Seiken Co., Tokyo, Japan) to remove nonspeciﬁc
inhibitors. Three volumes of receptor-destroying enzyme were added to 1
volume of human sera and incubated overnight at 37C. Samples were then
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Life Technologies, Grand Island, NY) were added, resulting in a 1:10 dilution
of each serum sample. The sera were serially diluted 2-fold up to a ﬁnal
dilution of 1:5120. Antigens used in the HI assay were b-propiolactane
inactivated inﬂuenza A viruses: A/Wisconsin/15/2009 X-183 (H3N2) and
A/California/07/2009 NYMC X-179A (H1N1pdm09) and the ether-treated
inﬂuenza B antigenB/Brisbane/60/2008 (Victoria lineage) (available at
Inﬂuenza Reagent Resource, http://www.inﬂuenzareagentresource.org).
Each antigenwas standardized to have 4 HA units/25 mL, and then 25 mL was
added to all wells containing diluted sera. The plates were mechanically
shaken for 10 seconds and incubated at room temperature for 15 minutes. A
total of 50 mL of a 0.5% solution of turkey red blood cells (University of
Georgia) was added to each well, the plates weremechanically shaken for 10
seconds, and incubated at room temperature for 30 minutes to allow the
RBCs to settle. After 30 minutes, the plates were tilted at a 45 to 60 angle
and observed for the presence or absence of hemagglutination. The HI titer
was calculated as the reciprocal of the highest dilution of antiserum that
completely inhibits hemagglutination. Positive seroconversion was deﬁned
as a 4-fold rise of HI Ab titer in postvaccination sera compared with
prevaccination.IFN-g ELISpot Responses
ELISpot was performed using cryopreserved PBMCs collected at 8 weeks
after vaccination. PBMCs were thawed using standard techniques and rested
overnight at 37C in RPMI 1640 with 10% fetal bovine serum (FBS). After this,
cells were washed with PBS and resuspended in RPMI. The 0.25  106 cells
were plated on Millipore’s Multiscreen ﬁlter plates and stimulated with a
0.8 ug/mL concentration of the 2010 inﬂuenza vaccine for 15 to 20 hours
overnight at 37C. Poke Weed Mitogen (20 ng/mL), a known stimulator of
IFN-g, was used as a positive control for each sample, and resting cells were
used as a negative control. After the overnight stimulation with vaccine, the
cells were washed 3 times with a 0.05% PBS Tween-20 solution. IFN-g was
detected and quantitated using sandwich immune-enzyme technology
(biotinylated Ab with detection using streptavidin-alkaline phosphatase)
according to the manufacturer’s recommendations (R&D Systems, Minne-
apolis, MN). Filter plates were then developed using a 5-bromo-4-chloro-30-
indolyphosphate and nitro-blue tetrazolium substrate, which resulted in
spot formation. Responses were considered positive if they were 4 times
above the background (resting control) and if the patient showed response
to the Poke Weed Mitogen stimulation.Statistical Analysis
Factors were compared across randomization group using the chi-
square test or Fisher exact test when appropriate. Univariate comparison
of factors by serological response deﬁned as H3N1, H1N1, b/Vic at 8 weeks
by a 4-fold increase, or ELISpot at 8 weeks deﬁned as a positive response
were carried out by the chi-square test or Fisher exact test when expected
cell counts were too small. Logistic regression analysis was used to look at
the independent effect on response by the randomization group (1 vs 2
vaccinations) controlling for the following factors: years from trans-
plantation to infusion (continuous per year or categorical (<1 year vs >1
year depending on frequencies), gender (male vs female), age (<18 vs 18),
use of TBI in the conditioning regimen, disease risk (standard vs high-risk vs
nonmalignant disease), donor type (cord blood vs other), use of steroids (no
vs yes), B and T cell subsets, and cytomegalovirus (CMV) serostatus (patient/
donor both negative vs other).RESULTS
Study Population
In all, 73 patients who underwent allo-HCT were enrolled
in the study between September 2010 and March 2011.
However, due to relapse (n¼ 1), desire to bewithdrawn from
the study (n ¼ 2), missed follow-up visits (n ¼ 4), and
physician discretion to not give a second vaccine dose (n ¼
1), a total of 65 patients were evaluable, with blood samples
available for correlative studies. Demographic data on the
study population are listed in Table 1. Patients randomized to
receive either 1 vs 2 vaccine doses did not differ in age,
gender, time from transplantation, conditioning intensity,
GVHD prophylaxis, or stem cell source. Before randomiza-
tion, patients were stratiﬁed based on age and current
steroid use, so each group contained equal numbers of
pediatric patients and those on varying doses (andschedules) of prednisone at the time of study enrollment
(n ¼ 22; Supplemental Table S1).
Vaccine-Associated Ab Responses
Before vaccination and at 4 and 8 weeks after vaccination,
the HI assay was used to detect inﬂuenza-speciﬁc Ab titers.
Two different approaches were used to quantify vaccine-
speciﬁc response including seroprotection and seroconver-
sion. Comparing patients who received a single vaccine dose
vs those that received 2 doses, there were no signiﬁcant
differences in the rates of seroprotection (vaccine titer of
>1:40 at 8 weeks) for inﬂuenza H3 (19% vs 19%), H1N1 (32%
vs 32%), and (32% vs 23%). Similarly, the rate of seroconver-
sion (>4 fold increase in Ab titers), at week 8 after vaccina-
tion was no different for inﬂuenza H3 (13% vs 22%, P ¼ .32)
H1N1 (31% vs 31%, P ¼ .99) and the B/Victoria strains (16% vs
25%, P ¼ .55), for recipients of one vs two vaccines respec-
tively (Figure 1A).
There was a higher likelihood of vaccine seroconversion
in patients that were 1 year from transplantation (n ¼ 29)
compared to those who were<1 year (n¼ 36) (Figure 1B). In
fact, none of the patients vaccinated <1 year from trans-
plantation showed seroconversion to the A/H3N2 virus vs
39% of patients vaccinated 1 year (P ¼ .001). Similarly, only
6% and 8% of patients in the <1 year group seroconverted to
the A/H1N1 and B/Victoria, respectively, whereas 64% (P ¼
.001) and 39% (P ¼ .003) seroconverted in the 1 year group,
respectively (Figure 1B). Although the seroconversion rates
were low for patients vaccinated <1 year after trans-
plantation, the response to any 1 of the 3 vaccine strains did
not differ for patients vaccinated 2 to 6 months after trans-
plantation compared to those vaccinated 6 to 12 months
after transplantation (12% vs 30%; P ¼ .43). Conversely,
because responses were more robust in patients vaccinated
>1 year after transplantation, subgroup analysis was per-
formed to determine if there was a differences in serocon-
version rates (to any 1 of the 3 vaccine strains) for patients
randomized to receive 1 vs 2 vaccines; however, no differ-
ences were observed (75% vs 63%, P ¼ .48).
In univariate analysis, stem cell sourcewas also associated
with seroconversion because matched related donor (MRD)/
matched unrelated donor (MUD) recipients were more likely
to show A/H3N2 responses compared to UCB recipients (24%
vs 4%; P ¼ .04). Analogous trends were observed with
responses to A/H1N1 in which 39% vs 17% (P ¼ .07), respec-
tively. There was no difference between the 2 stem cell
sources in the B/Victoria group (Figure 1C). Other parameters
not associated with Ab responses included recipient age,
conditioning intensity (RIC vs MA), disease risk group, or use
of steroids (not shown).
Before vaccination, blood was collected for immunophe-
notyping to examine B, T, and NK cells and their subsets. As
shown in Table 2, higher numbers of B cells (total CD19þ
fraction, unswitchedmemory B cells, and naïve B cells) at the
time of ﬁrst vaccination were more likely to develop Ab
responses (P ¼ .03, P ¼ .03, and P ¼ .03, respectively). There
was no correlation between Ab responses and the total
numbers of CD3, CD4, and CD8 cells before vaccination (P ¼
.26; P¼ .07, and P¼ .19, not shown). For CD4þ T cells, patients
in the highest tertile (>347 cells/m2) were more likely to
develop inﬂuenza Abs after vaccination (P ¼ .04), but the
absolute numbers of naïve, effector memory, or effector
memory CD45RAþ cells before vaccination were not associ-
ated with Ab responses (P ¼ .26, P ¼ .14, P ¼ .95, not shown).
Likewise, there was no correlation between the absolute
Figure 1. Variables associated with serological vaccine immune responses. (A) Number of vaccines delivered. (B) Time from transplantation to time of vaccination.
(C) Donor source (umbilical cord blood [UCB] vs matched related donor [MRD]/unrelated donor [URD]). (D) Recipient age.
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memory, effector memory, or effector memory CD45RAþ) or
NK cells before transplantation and vaccine responses (P ¼
.26, P ¼ .32, P ¼ .23, P ¼ .67, and P ¼ .23, respectively).
In multivariate analysis, Ab responses to any 1 of the 3
vaccine strains were signiﬁcantly higher in patients who
were 1 year from transplantation at time of vaccination
(relative risk, 15.5; 95% conﬁdence interval [CI], 3.2-76; P <
.01; Table 3). Patients who had higher numbers of CD19þ
B cells before vaccination were more likely to have AbTable 2
B Cell Subsets and Vaccine-Speciﬁc Immune Responses
Factors 4  Ab
Response
P Value ELISpot
Response
P Value
Total CD19 .03 <.01
1st Tertile (<71.4) 3 (15%) 13 (65%)
2nd Tertile (71.4-560) 9 (43%) 12 (57%)
3rd Tertile (560þ) 11 (55%) 3 (15%)
Switched memory .12 .22
1st Tertile 4 (20%) 11 (55%)
2nd Tertile 9 (43%) 11 (52%)
3rd Tertile 10 (50%) 6 (30%)
Unswitched memory .03 <.01
1st Tertile (<0.92) 3 (15%) 14 (70%)
2nd Tertile (0.92-6.2) 9 (43%) 10 (48%)
3rd Tertile (6.2þ) 11 (55%) 4 (20%)
Naïve .03 .02
1st Tertile (<61.2) 3 (15%) 14 (70%)
2nd Tertile (61.2-480) 9 (43%) 9 (43%)
3rd Tertile (480þ) 11 (55%) 5 (25%)
Double negative .14 <.01
1st Tertile (<7) 4 (20%) 15 (75%)
2nd Tertile (7-35) 10 (48%) 8 (38%)
3rd Tertile (35þ) 9 (45%) 5 (25%)
The number of B cells (and subset) in the blood before vaccination were
divided into tertiles, and the percentage of patients with either Ab or ELI-
Spot response are shown. Differences in the groups were determined using
the Fisher exact test.responses (Table 3). However, due to the correlation between
the various B cell subpopulations, we were not able to
independently investigate the impact of these subpopula-
tions on vaccine responses. Vaccine-speciﬁc immune
responses did not differ between the randomization groups
(1 vs 2 vaccines), steroid usage, or the numbers of T cells
(or the T cell subsets) in the blood before vaccination (not
shown).
T cell Vaccine-Associated INF-g Responses
A total of 64 patients had 8-week postvaccination
samples evaluable for IFN-g ELISpot testing (n ¼ 32 inTable 3
Factors Associated with Serological Vaccine Response
Factor Odds Ratio of
Responding
95% CI P Value
Randomization group
Single shot 1.0
Double shot 1.0 (0.2-4.4) .96
Years from transplantation
to infusion
<1 year 1.0
1 year 15.5 (3.2-76.4) <.001
Steroid use
No 1.0
Yes 0.9 (0.7-1.2) .52
CD19
1st Tertile (<71.4) 1.0
2nd Tertile (71.4-560) 5.0 (0.9-28.8) .07
3rd Tertile (560þ) 18.0 (1.9-169.7) .01
CD4þ
1st Tertile (<255) 1.0
2nd Tertile (255-669) 1.1 (0.2-6.2) .88
3rd Tertile (669þ) 1.4 (0.2-10.7) .77
CI indicates conﬁdence interval.
Multiple variable analysis models were constructed as described in the
methods taking into account the variables described in the methods.
Figure 2. Variables associated with IFN-g vaccine-immune responses. (A) Number of vaccines delivered. (B) Time from transplantation to time of vaccination.
(C) Donor source (umbilical cord blood [UCB] vs matched related donor [MRD]/unrelated donor [URD]). (D) Recipient age.
Table 4
Factors Associated with IFN-g Vaccine Response
Factor Odds Ratio of
Responding
95% CI P Value
Randomization group
Single shot 1.0
Double shot 0.6 (0.2-2.3) .50
Donor type
MRD/URD 1.0
UCB 0.1 (0.02-0.5) .004
Years from transplantation
to infusion
<1 year 1.0
1 year 2.7 (0.7-10.6) .17
Steroid use
No 1.0
Yes 1.1 (0.7-1.5) .79
CD19
1st Tertile (<71.4) 1.0
2nd Tertile (71.4-560) 0.3 (0.1-1.2) .09
3rd Tertile (560þ) 0.1 (0.02-1.0) .05
MRD indicates matched related donor; URD, unrelated donor; UCB, umbil-
ical cord blood.
Multiple variable analysis models were constructed as described in the
methods taking into account the variables described in the methods.
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responses, there were no statistical differences in responses
between recipients that received 1 or 2 vaccinations (44% vs
47%; P ¼ .84) (Figure 2A).
Again, the time from transplantation to vaccination was
associated with vaccine response because patients 1 year
from transplantation were more likely to show vaccine-
induced IFN-g production (61% vs 33%; P ¼ .03; Figure 2B).
Of the patients <1 year from transplantation, there were no
differences in ELISpot responses for those vaccinated 2 to 6
months vs 6 to 12 months (28% vs 40%; P ¼ .36). As ELISpot
responses were better in patients vaccinated >1 year after
transplantation, subgroup analysis was performed to deter-
mine whether a second vaccine affected responses, but there
were no differences between patients that received 1 vs 2
vaccines (67% vs 59%; P ¼ .58). Additionally, the stem cell
source was also signiﬁcantly associated with IFN-g vaccine
responses, as 63% of MRD/MUD recipients showed IFN-g
production, compared to only 13% of UCB recipients (P <
.001; Figure 2C).
In contrast to the Ab responses, T cell-based vaccine
responses (IFN-g) were associated with recipient age in the
univariate analysis. Patients who were 18 years old at the
time of vaccination were more likely to have a positive ELI-
Spot. In fact, 57% of patients in this group showed IFN-g
response, whereas only 12% of those aged <18 years old did
so (P ¼ .001; Figure 2D). Although adult patients were more
likely to have received RIC, there was no association between
IFN-g responses between MA or RIC regimens (41% vs 53%;
P ¼ .53).
Similar to Ab responses, the absolute numbers of B cells,
T cells, and NK cells (and their subpopulations) were strati-
ﬁed into tertiles. As shown in Table 2, the absolute numbers
of CD19þ B cells before vaccinationwere inversely correlated
with IFN-g production (P < .01). Patients who had lower
numbers of B cell subpopulations (naïve, unswitched
memory, and double-negative B cells) at the time of ﬁrstvaccination were more likely to develop IFN-g responses
(Table 2). There was no correlation between the prevacci-
nation numbers of CD3, CD4, and CD8 cells (P ¼ .36; P ¼ .80,
and P ¼ .16, data not shown). Likewise, no differences were
noted for IFN-g responses in the CD4 or CD8 subpopulations
(naïve, central memory, or effector memory CD45RAþ) or in
the NK cell fraction (data not shown).
Multivariate analysis conﬁrmed the association of stem
cell source for vaccine-associated T cell IFN-g response as
responses for UCB were less likely than MRD/MUD (relative
risk, 0.1; 95% CI, 0.02-0.5; P ¼ .004; Table 4). Time from
transplantation and steroid usewere not signiﬁcant variables
in the multivariate analysis. As in the univariate analysis,
there was a signiﬁcant inverse correlation between the
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(Table 4).
DISCUSSION
We tested the hypothesis that a second vaccinationwould
bolster inﬂuenza-speciﬁc immune responses by performing
a randomized trial in patients who underwent allo-HCT in
which patients received either 1 or 2 inﬂuenza vaccine doses.
There was no evidence for increased serologic or T cell-
mediated immune responses for patients who received
a second, “booster” vaccine compared to those that received
1 vaccine dose. Secondary aims of this study were to deter-
mine whether clinical and biological parameters predicted
vaccine responses. Clinical variables associated with
responses included the time from transplantation to vacci-
nation, in which patients further from the transplantation
date were more likely to have a protective rise in Ab titers
and IFN-g production. Another signiﬁcant variable was the
stem cell source (UCB vs PBSCs/bone marrow [BM]), inwhich
UCB recipients showed less vaccine-associated IFN-g
production but showed no difference in Ab production in
multivariate analysis. We also found that, in general, higher
numbers of B cells (and B cell subsets) at the time of vacci-
nation were associated with Ab responses, and lower
numbers of B cells predicted IFN-g production. Surprisingly,
the numbers of T cells (or their subsets) were not correlated
with vaccine responses.
In 1993, Engelhard et al. [19] ﬁrst examined serological
responses after a 2-dose regimen of the inﬂuenza vaccine.
Although they found no efﬁcacy for this approach, this study
was performed in the context of in vivo lymphodepletion (ie,
alemtuzumab). Given that that T and B cells are important for
vaccine-associated responses [21], we tested this hypothesis
in lymphocyte-replete allo-HCT recipients. Similar to
Engelhard et al. [19] we found that a second vaccine dosewas
not beneﬁcial, at least when given 4 weeks apart, as sug-
gested by the Centers for Disease Control pediatric guidelines
for vaccine-naïve children [16]. Although not tested, Ljung-
man et al. [22] proposed that a second vaccine dose might be
given to patients initially vaccinated <6 months from
transplantation during an inﬂuenza outbreak or upcoming
inﬂuenza season. Given that a signiﬁcant proportion of
patients in our study fell into this category, our data do not
support this approach. In contrast, others such as de
Lavallade et al. [23] have recently demonstrated a beneﬁt to
a booster dose of A/H1N1 vaccine among 97 adult patients
with hematologic malignancies receiving chemotherapy and
in a smaller number after allogeneic allo-HCT. Importantly,
only 2 patients who underwent allo-HCT in this series were
receiving immune-suppressive therapy, and neither respon-
ded to the vaccine. A considerable proportion of patients in
our cohort were vaccinated either early after transplantation
and were still on immune suppression (26%) or were UCB
recipients (39%), making it difﬁcult to compare the 2 studies.
Similar to previous studies of inﬂuenza vaccination in
patients who underwent allo-HCT [12,13,19,21], our sero-
conversion rates were higher among patients who were
farther from the time of HCT. Such ﬁndings are not entirely
surprising knowing that post-HCT immune reconstitution is
a protracted process. Although immunoglobulin responses
are believed to be the integral component in protective
inﬂuenza-speciﬁc immunity [24], we observed measurable
and signiﬁcant T cell responses in some patients vaccinated
as early as 60 days after transplantation. In fact, we could
detect no difference in either Ab or IFN-g responses whencomparing patients vaccinated 2 to 6 months after trans-
plantation to those vaccinated 6 to 12 months. Although
the numbers of patients were small, these results might
suggest that vaccination earlier than suggested by the Center
for International Blood and Marrow Transplant Research
guidelines [15] may be efﬁcacious, but further studies are
needed to conﬁrm these ﬁndings.
Interestingly, we found that the number of CD19þ cells
were directly correlated to the ability to seroconvert and
inversely correlated to the ability to produce IFN-g. Taken at
face value, these ﬁndings appear to be logical (more B cells
are associated with serological responses, while less B cells
may be associated with T cell responses), however, the exact
explanation for these ﬁndings is not entirely clear. To our
knowledge, these ﬁndings represent novel data; however,
few transplantation studies have addressed the role of B cell
reconstitution on vaccine-associated responses. Perhaps
B cell recovery, as measured here, is a surrogate for more
complete immune recovery and reﬂective of the likelihood of
vaccine responses. Related to this, we have recently
demonstrated that in the BM early after transplantation,
B cell precursors (hematogones) are associated with less
GVHD and improved UCB transplantation outcomes [25],
whereas others have recently hypothesized that B cells
regulate/attenuate T cell responses in the setting of trans-
plantation [26]. Somewhat surprisingly, the CD4þ count was
not associated with the likelihood of seroconversion. This is
in contrast to Mohty et al. [27] who noted a signiﬁcant naïve
CD4þ count of >150/m3 with seroconversion. Importantly,
prevaccination numbers of B cells were not assessed in
the above-mentioned study. For other vaccines, such as the
7-protein-valent-pneumococcal vaccine, Pao et al. [28]
demonstrated that recovery of CD4þ cells >200/m3 was
associated with a response (11 of 19 patients vs 0 of 8);
however, above that level, there was no association with
increased response. In our study, more than 30% of patients
vaccinated early after transplantation showed IFN-g
responses, thus, the close proximity of vaccination from
transplantation suggests that this approach may provide
some beneﬁt to allo-HCT recipients early after trans-
plantation. Likewise, Avetisyan et al. [13] demonstrated
similar results in patients 3 months after transplantation.
Thus, we conclude that it is safe and potentially effective to
use inﬂuenza vaccination as early as 2 months from trans-
plantation. It is important to note that, in our study,
a majority of patients who were vaccinated less than 1 year
from their transplantation were clustered around day 60 to
100 at study entry (21 of 31 patients), making it impossible to
examine whether other time points after transplantation
were associated with vaccine responses.
Interestingly, we observed a signiﬁcant difference in
the immune responses of BM/peripheral blood stem cell
transplantation recipients compared with UCB recipients.
Data are scarce regarding UCB transplantation recipients’
immune response to the inﬂuenza vaccine [29]. Avetisyan
et al. [13] included only 3 UCB recipients in their study but
did not speciﬁcally specify their results. Issa et al. [30] also
had only 3 of 82 patients who had undergone UCB trans-
plantations. Given that 39% of patients in our studywere UCB
recipients, wewere able to separate responses based on stem
cell source, although still small sample numbers. UCB
recipients were less likely to show a positive ELISpot assay.
Similar ﬁndings have been noted for polyclonal mitogens
(SEB) and cytomegalovirus peptide responses in UCB vs BM
recipients [31]. These ﬁndings are consistent with prior
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to produce IFN-g relative to peripheral blood T cells, due to
a reduction in nuclear factor of activated T cells (NFAT)-
associated responses [32,33].
Another seemingly surprising ﬁnding in our study was
that corticosteroid usage did not negatively affect the prob-
ability of immune response to the inﬂuenza vaccine. Nichols
et al. [8] previously showed that corticosteroids were
a protective factor in evaluating for progression of upper
respiratory tract infection symptoms to the lower respiratory
tract. Additionally, Machado et al. [12] demonstrated that
steroid use and inﬂuenza vaccine were independent factors
associated with not developing inﬂuenza. In multivariate
analysis, we found that the use of steroids did not prevent
either B or T cell-speciﬁc inﬂuenza responses. This is in line
with Issa et al. [30] results, which also did not observe
a difference in response to the A/H1N1 vaccine in partici-
pants whowere on steroids for acute GVHD or chronic GVHD
vs those that were not.
In this randomized clinic trial, we found that 2 doses of
inﬂuenza vaccine, separated by 1 month, did not confer
better vaccine-associated T or B cell responses. In contrast,
allo-HCT recipients who were >1 year from the time of
transplantation and those who received MRD/URD were
more likely to respond. Given the evidence that time from
transplantation is the most signiﬁcant variable in the likeli-
hood of an immune response to the inﬂuenza vaccine [14,21],
the timing of vaccination seems to be the easiest way to
manipulate a response. Traditionally, our center has taken
the approach of administering the ﬁrst opportunity after
day þ60 to vaccinate transplantation recipients once the
seasonal inﬂuenza vaccine is available, usually starting in
early October each year. Perhaps consideration should be
given to defer vaccination until December or January, thus
allowing patients to progress further from their trans-
plantation so as to increase the likelihood of vaccine
responses. This approach might be inﬂuenced by an early
epidemic of inﬂuenza or predicted vaccine shortages.
Unfortunately, we were not able to correlate these results
with actual acquired inﬂuenza infections, given that this
study was not powered to detect such differences and that
many patients were not primarily followed at our center.
However, as therewas some evidence of immune response in
our patients and no adverse effects, it is reasonable to
vaccinate at day þ60, with the advisory given to this pop-
ulation that the vaccination is unlikely to be sufﬁcient. Still
other approaches that might be useful to induce vaccine-
speciﬁc immune responses are the high-dose vaccine that
is now approved for elderly patients. To date, this vaccine has
not been tested and might provide better inﬂuenza-speciﬁc
immunity, but randomized clinical trials are needed.ACKNOWLEDGMENTS
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